Xalud Therapeutics Announces Award of $690,000 Grant from the NIH to Study Multiple Sclerosis

By February 8, 2013Press Release
ms
SAN FRANCISCO, California. February 8, 2013 – Xalud Therapeutics, Inc., a private biotechnology company, announced that it had been awarded a $690,000 SBIR grant from the National Institute of Neurological Disorders and Stroke, a division of the National Institutes of Health. The grant, which will be paid over two years, will support Xalud’s research into the use of its lead product candidate, XT-101 for the treatment of multiple sclerosis, including its applicability for the treatment of pain and gait disorders associated with MS.

XT-101 harnesses the power of the natural anti-inflammatory protein interluekin- 10 (IL-10) to treat neuro-inflammatory diseases such as neuropathic pain, MS and ALS. In pre-clinical studies in leading animal models of MS, XT-101 has shown the ability to eliminate pain associated with MS, halt disease progression and reverse paralysis caused by the disease.

Xalud Therapeutics, Inc. is an early stage biotechnology company based in San Francisco, CA. Using technologies developed by Dr. Linda Watkins at the University of Colorado Boulder, Xalud is developing novel therapies for the treatment of neuropathic pain and other diseases of the central nervous system. To learn more, please go to www.xaludthera.com .


Media Contact:
Peter Heinecke Xaludinfo@xaludthera.com

###